Corporate Logo(source: intocell.com)
IntoCell, a platform company specializing in ADC(antibody-drug conjugate) technology, announced on the 25th that it has submitted its securities registration statement to the Financial Services Commission and officially begun the process for its public offering as part of its goal to list on the KOSDAQ.
According to the company, IntoCell, which marks its 10th anniversary this year, is a leading ADC platform research and development firm. Founded by CEO Park Tae-kyo, who played a pivotal role in inventing the core platform technology "ConjuALL" and is a co-founder of Rigacell Bio, the company has developed proprietary platform technologies over the past decade, including Opas, PMT(Payload Modification Technology), and various mechanisms of action(MOA), positioning itself for a leap toward becoming a global bio company.
ADC, a next-generation cancer treatment consisting of an antibody, drug, and linker, has gained attention in the oncology market due to its ability to selectively target cancer cells, thereby enhancing efficacy and reducing side effects. Successful development of ADC requires advanced linker technology, which has high technical difficulty, limiting the number of companies that have succeeded in this field.
One of IntoCell's unique linker platforms, "OHPAS™," has shown superior efficacy duration and blood stability compared to competitor platforms. Notably, it can conjugate phenolic drugs that could not be linked with existing technologies, and its high versatility allows conjugation with amine-based drugs through the introduction of a spacer, making it compatible with a wide range of drugs and allowing for superior efficacy in targeting multiple types of cancer, according to the company.
Additionally, the platform overcomes the limitations of previous linker technologies by employing a design where substances detach under specific conditions, such as cancer cells, providing a stable product in the bloodstream while delivering efficacy at the targeted site.
Another ADC platform, PMT, prevents interactions between the drug and normal cells, allowing for selective absorption by the ADC. Existing ADCs often react with normal cells, leading to non-selective absorption of the drug, reducing efficacy and increasing the risk of side effects. However, PMT technology enhances selectivity by 115 times, significantly reducing normal cell mortality and maximizing the anticancer effect.
Thanks to its focus on advanced ADC platform R&D, IntoCell earned an A and A rating in the technical evaluation for KOSDAQ listing last year. The company plans to use the funds raised from the listing for enhancing platform technology R&D, advancing key pipelines, and infrastructure development.
IntoCell plans to offer 1.5 million shares in this public offering. The price range for the offering is set between 12,500 won and 17,000 won per share. Mirae Asset Securities is the lead underwriter for the listing.
Corporate Logo(source: intocell.com)
IntoCell, a platform company specializing in ADC(antibody-drug conjugate) technology, announced on the 25th that it has submitted its securities registration statement to the Financial Services Commission and officially begun the process for its public offering as part of its goal to list on the KOSDAQ.
According to the company, IntoCell, which marks its 10th anniversary this year, is a leading ADC platform research and development firm. Founded by CEO Park Tae-kyo, who played a pivotal role in inventing the core platform technology "ConjuALL" and is a co-founder of Rigacell Bio, the company has developed proprietary platform technologies over the past decade, including Opas, PMT(Payload Modification Technology), and various mechanisms of action(MOA), positioning itself for a leap toward becoming a global bio company.
ADC, a next-generation cancer treatment consisting of an antibody, drug, and linker, has gained attention in the oncology market due to its ability to selectively target cancer cells, thereby enhancing efficacy and reducing side effects. Successful development of ADC requires advanced linker technology, which has high technical difficulty, limiting the number of companies that have succeeded in this field.
One of IntoCell's unique linker platforms, "OHPAS™," has shown superior efficacy duration and blood stability compared to competitor platforms. Notably, it can conjugate phenolic drugs that could not be linked with existing technologies, and its high versatility allows conjugation with amine-based drugs through the introduction of a spacer, making it compatible with a wide range of drugs and allowing for superior efficacy in targeting multiple types of cancer, according to the company.
Additionally, the platform overcomes the limitations of previous linker technologies by employing a design where substances detach under specific conditions, such as cancer cells, providing a stable product in the bloodstream while delivering efficacy at the targeted site.
Another ADC platform, PMT, prevents interactions between the drug and normal cells, allowing for selective absorption by the ADC. Existing ADCs often react with normal cells, leading to non-selective absorption of the drug, reducing efficacy and increasing the risk of side effects. However, PMT technology enhances selectivity by 115 times, significantly reducing normal cell mortality and maximizing the anticancer effect.
Thanks to its focus on advanced ADC platform R&D, IntoCell earned an A and A rating in the technical evaluation for KOSDAQ listing last year. The company plans to use the funds raised from the listing for enhancing platform technology R&D, advancing key pipelines, and infrastructure development.
IntoCell plans to offer 1.5 million shares in this public offering. The price range for the offering is set between 12,500 won and 17,000 won per share. Mirae Asset Securities is the lead underwriter for the listing.